Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, generic, branded generic, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular, and anti-infective therapeutic categories, as well as dermatology and plastic surgery. It also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians’ offices. In addition, Allergan plc is developing ocular implants that reduce intraocular pressure associated with glaucoma; and an intranasal neurostimulation device, as well as other dry eye products. Allergan plc has a global development and commercialization agreement with AstraZeneca Plc regarding investigational antibiotic combination ATM-AVI. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.